What next for botulism vaccine development?

Expert Review of Vaccines

Volumn 12, Issue 5, 2013, Pages 481-492

  Webb, Robert P ^a   Smith, Leonard A ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

botulinum neurotoxin; botulism; mucosal vaccine; subunit vaccine; toxoid vaccine; viral vaccine

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; TETANUS TOXIN; TOXOID; VIRUS VECTOR;

ANTIBODY RESPONSE; BOTULISM; DRUG RECEPTOR BINDING; HUMAN; IMMUNOGENICITY; INOCULATION; NONHUMAN; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTECTION; PROTEIN DOMAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROCONVERSION; SEROTYPE; SINGLE DRUG DOSE; VACCINATION;

BACTERIAL VACCINES; BOTULISM; DRUG DISCOVERY; HUMANS; UNITED STATES; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84877624981     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.13.37     Document Type: Review

References (93)

1. Johnson EA. Clostridium botulinum and Clostridium tetani. In: Topley and Wilson's Microbiology and Microbial Infections. Volume 8. Borriello SP, Murray PR, Funke G (Eds). Hodder Arnold Publishers, London, UK, 1035-1088 (2005).
2. Stenmark P, Dupuy J, Imamura A, Kiso M, Stevens RC. Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog. 4(8), e1000129 (2008).
3. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 312(5773), 592-596 (2006).
4. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 580(8), 2011-2014 (2006).
5. Fernandez-Salas E, Garay PE, Iverson C, Malik SZ, Steward LE, Aoki KR. Identification of FGFR3 as a putative receptor for botulinum neurotoxin type A uptake in neuronal cells. Presented at: The 5th International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, CO, USA, 22-25 June 2005.
6. Dong M, Tepp WH, Liu H, Johnson EA, Chapman ER. Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J. Cell Biol. 179(7), 1511-1522 (2007).
7. Jin R, Rummel A, Binz T, Brunger AT. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444(7122), 1092-1095 (2006).
8. Fischer A, Montal M. Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J. Biol. Chem. 282(40), 29604-29611 (2007).
9. Galloux M, Vitrac H, Montagner C, et al. Membrane Interaction of botulinum neurotoxin A translocation (T) domain. The belt region is a regulatory loop for membrane interaction. J. Biol. Chem. 283(41), 27668-27676 (2008).
10. Simpson LL. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 44, 167-193 (2004).
11. Arnon SS, Schechter R, Inglesby TV, et al.; Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285(8), 1059-1070 (2001).
12. Woodruff BA, Griffin PM, McCroskey LM et al. Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975-1988. J. Infect. Dis. 166(6), 1281-12866 (1992).
13. Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am. J. Med. 76(5), 794-798 (1984).
14. Chang GY, Ganguly G. Early antitoxin treatment in wound botulism results in better outcome. Eur. Neurol. 49(3), 151-153 (2003).
15. Fox CK, Keet CA, Strober JB. Recent advances in infant botulism. Pediatr. Neurol. 32(3), 149-154 (2005).
16. CDC. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR 59(10), 229 (2010).
17. Sevcik C, Salazar V, Díaz P, D'Suze G. Initial volume of a drug before it reaches the volume of distribution: pharmacokinetics of F(ab́)2 antivenoms and other drugs. Toxicon 50(5), 653-665 (2007).
18. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov. Disord. 3(4), 333-335 (1988).
19. Rusnak J, Smith LA. Botulinum neurotoxin vaccines: Past history and recent developments. Hum. Vaccin. 5(12), 794-805 (2009).
20. Smith LA. Botulism and vaccines for its prevention. Vaccine 27(Suppl. 4), D33-D39 (2009).
21. CDC. Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR 60(42), 1454-1455 (2011).
22. Torii Y, Tokumaru Y, Kawaguchi S, et al. Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. Vaccine 20(19-20), 2556-2561 (2002).
23. Edelman R, Wasserman SS, Bodison SA, Perry JG, O'Donnoghue M, DeTolla LJ. Phase II safety and immunogenicity study of type F botulinum toxoid in adult volunteers. Vaccine 21(27-30), 4335-4347 (2003).
24. Keller JE. Characterization of new formalin-detoxified botulinum neurotoxin toxoids. Clin. Vaccine Immunol. 15(9), 1374-1379 (2008).
25. Held DM, Shurtleff AC, Fields S, et al. Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B. Clin. Vaccine Immunol. 17(6), 930-936 (2010).
26. Jones RG, Liu Y, Rigsby P, Sesardic D. An improved method for development of toxoid vaccines and antitoxins. J. Immunol. Methods 337(1), 42-48 (2008).
27. Fairweather NF, Lyness VA, Maskell DJ. Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect. Immun. 55(11), 2541-2545 (1987).
28. Clare JJ, Rayment FB, Ballantine SP, Sreekrishna K, Romanos MA. High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene. Biotechnology (NY) 9(5), 455-460 (1991).
29. Dertzbaugh MT, West MW. Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine 14(16), 1538-1544 (1996).
30. Tavallaiea M, Chenalc A, Gillet D, et al. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Letters 572(1-3), 299-306 (2004).
31. Clayton MA, Clayton JM, Brown DR, Middlebrook JL. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect. Immun. 63(7), 2738-2742 (1995).
32. Boles J, West M, Montgomery V, et al. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon 47(8), 877-884 (2006).
33. Morefield GL, Tammariello RF, Purcell BK, et al. Protection from multiple bacterial and toxin-mediated diseases using an intradermal vaccine array. J. Immune Based Ther. Vacc. 6(5), 1-11 (2008).
34. Shearer JD, Manetz TS, House RV. Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B). Vaccine 30(11), 1917-1926 (2012).
35. Hart MK, Saviolakis GA, Welkos SL, House RV. Advanced development of the rF1V and rBV A/B vaccines: progress and challenges. Adv. Prev. Med. 2012, 731604 (2012).
36. Mckee KT Jr, Greenberg RN, Swiderski W, Plummer EA, Starner RA, Henderson I. Initial evaluation of a recombinant Clostridium botulinum A/B vaccine (rBV A/B) in healthy volunteers. Presented at: The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, USA, 16-19 December 2005.
37. Swiderski W, Greenberg RN, Hoover DL, McKee KT, Starner RA, Henderson I. Impact of adjuvant and immunogenicity of a recombinant botulinum vaccine A/B in healthy adult volunteers. Presented at: The 42nd Annual Interagency Botulinum Research Coordinating Committee Meeting (IBRCC), Baltimore, MD, USA, 5-8 December 2005.
38. Shearer JD, Vassar ML, Swiderski W, Metcalfe K, Niemuth N, Henderson I. Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B). Vaccine 28(45), 7313-7318 (2010).
39. Sanford DC, Barnewall RE, Vassar ML et al. Inhalational botulism in rhesus macaques exposed to botulinum neurotoxin complex serotypes A1 and B1. Clin. Vaccine Immunol. 17(9), 1293-1304 (2010).
40. Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol. Immunol. 44(5), 1029-1041 (2007).
41. Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol. Immunol. 45(15), 3878-3888 (2008).
42. Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology 216(7), 782-792 (2011).
43. Atassi MZ, Jankovic J, Steward LE, Aoki KR, Dolimbek BZ. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology 217(1), 17-27 (2012).
44. Adekar SP, Takahashi T, Jones RM, et al. Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS ONE 3(8), e3023 (2008).
45. Kiyatkin N, Maksymowych AB, Simpson LL. Induction of an immune response by oral administration of recombinant botulinum toxin. Infect. Immun. 65(11), 4586-4591 (1997).
46. Jensen MJ, Smith TJ, Ahmed SA, Smith LA. Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. Toxicon 41(6), 691-701 (2003).
47. Gilsdorf J, Gul N, Smith LA. Expression, purification, and characterization of Clostridium botulinum type B light chain. Protein Expr. Purif. 46(2), 256-267 (2006).
48. Webb RP, Smith TJ, Wright P, Brown J, Smith LA. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine 27(33), 4490-4497 (2009).
49. Shone C, Agostini H, Clancy J, et al. Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes. Infect. Immun. 77(7), 2795-2801 (2009).
50. Zhang P, Ray R, Singh BR, Li D, Adler M, Ray P. An efficient drug delivery vehicle for botulism countermeasure. BMC Pharm. 27(9), 1-9 (2009).
51. Ho M, Chang LH, Pires-Alves M, et al. Recombinant botulinum neurotoxin A heavy chain based delivery vehicles for neuronal cell targeting. Prot. Eng. Des. Sel. 24(3), 247-253 (2010).
52. Band PA, Blais S, Neubert TA, Cardozo TJ, Ichtchenko K. Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery. Protein Expr. Purif. 71(1), 62-73 (2010).
53. Zhou Y, Singh BR. Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain. Protein Expr. Purif. 34(1), 8-16 (2004).
54. Baldwin MR, Tepp WH, Pier CL, et al. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect. Immun. 73(10), 6998-7005 (2005).
55. Henkel JS, Tepp WH, Przedpelski A, Fritz RB, Johnson EA, Barbieri JT. Subunit vaccine efficacy against Botulinum neurotoxin subtypes. Vaccine 29(44), 7688-7695 (2011).
56. Baldwin MR, Tepp WH, Przedpelski A et al. Subunit vaccine against the seven serotypes of botulism. Infect. Immun. 76(3), 1314-1318 (2008).
57. Bade S, Rummel A, Reisinger C, et al. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates. J. Neurochem. 91(6), 1461-1472 (2004).
58. Singh BR, Thirunavukkarasu N, Ghosal K et al. Clostridial neurotoxins as a drug delivery vehicle targeting nervous system. Biochimie 92(9), 1252-1259 (2010).
59. Edupuganti OP, Ovsepian SV, Wang J et al. Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin. FEBS J. 279(14), 2555-2567 (2012).
60. Pier CL, Tepp WH, Bradshaw M, Johnson EA, Barbieri JT, Baldwin MR. Recombinant holotoxoid vaccine against botulism. Infect. Immun. 76(1), 437-442 (2008).
61. Foster KA. Engineered toxins: new therapeutics. Toxicon 54(5), 587-592 (2009).
62. Pickett A. Re-engineering clostridial neurotoxins for the treatment of chronic pain: current status and future prospects. BioDrugs 24(3), 173-182 (2010).
63. Pickett A, Perrow K. Towards new uses of botulinum toxin as a novel therapeutic tool. Toxins (Basel) 3(1), 63-81 (2011).
64. Chaddock JA, Purkiss JR, Friis LM, et al. Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A. Infect. Immun. 68(5), 2587-2593 (2000).
65. Chaddock JA, Purkiss JR, Duggan MJ, Quinn CP, Shone CC, Foster KA. A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors 18(2), 147-155 (2000).
66. Duggan MJ, Quinn CP, Chaddock JA et al. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J. Biol. Chem. 277(38), 34846-34852 (2002).
67. Somm E, Bonnet N, Martinez A, et al. A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J. Clin. Invest. 122(9), 3295-3306 (2012).
68. Smith TJ, Lou J, Geren IN, et al. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun. 73(9), 5450-5457 (2005).
69. Arndt JW, Jacobsen MJ, Abola EE, et al. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J. Mol. Biol. 362(4), 733-742 (2006).
70. Hill KK, Smith TJ, Helma CH, et al. Genetic diversity among botulinum neurotoxin-producing clostridial strains. J. Bacteriol. 189(3), 818-832 (2007).
71. Smith TJ, Hill KK, Foley BT, et al. Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids. PLoS One. 12(12), e1271 (2007).
72. Casey L, Wilson D. Biosafety in Microbiological and Biomedical Laboratories (Volume 5). US Department of Health and Human Services Publication No. (CDC), 21-1112 (2009).
73. Moss B, Smith GL, Gerin JL, Purcell RH. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 311(5981), 67-69 (1984).
74. Zen M, Xua Q, Eliasb MD, Pichicheroa ME, Simpson LL, Smith LA. Protective immunity against botulism provided by a single dose vaccination with an adenovirusvectored vaccine. Vaccine 25(43), 7540-7548 (2007).
75. Xu Q, Pichichero ME, Simpson LL, Elias M, Smith LA, Zeng M. An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Gene Ther. 16(3), 367-375 (2009).
76. Yu YZ, Zhang SM, Sun ZW, Wang S, Yu WY. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine 25(52), 8843-8850 (2007).
77. Yu Y, Yu J, Li N, Wang S, Yu W, Sun Z. Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors. Vaccine 27(44), 6148-6153 (2009).
78. Mustafa W, Al-Saleem FH, Nasser Z, et al. Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge. Vaccine 29(28), 4638-4645 (2011).
79. Ravichandran E, Al-Saleem FH, Ancharski DM, et al. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect. Immun. 75(6), 3043-3054 (2007).
80. Maddaloni M, Staats HF, Mierzejewska D et al. Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin. Immunol. 177(8), 5524-5532 (2006).
81. Jun S, Clapp B, Zlotkowska D, et al. Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication. Int. Immunol. 24(2), 117-128 (2012).
82. Clapp B, Golden S, Maddaloni M, Staats HF, Pascual DW. Adenovirus F protein as a delivery vehicle for botulinum B. BMC Immunol. 11, 36 (2010).
83. Yuki Y, Nochi T, Harada N, et al. In vivo molecular imaging analysis of a nasal vaccine that induces protective immunity against botulism in nonhuman primates. J. Immunol. 185(9), 5436-5443 (2010).
84. Yuki Y, Mejima M, Kurokawa S, et al. RNAi suppression of rice endogenous storage proteins enhances the production of rice-based Botulinum neutrotoxin type A vaccine. Vaccine 30(28), 4160-4166 (2012).
85. Toubaji A, Hill S, Terabe M, et al. The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine 25(31), 5882-5891 (2007).
86. Xu DZ, Zhao K, Guo LM, et al. A randomized controlled Phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE 3(7), e2565 (2008).
87. Wen YM. Antigen-antibody immunogenic complex: promising novel vaccines for microbial persistent infections. Expert Opin. Biol. Ther. 9(3), 285-291 (2009).
88. Li N, Yu YZ, Yu WY, Sun ZW. Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM-CSF gene adjuvant. Immunopharmacol. Immunotoxicol. 33(1), 211-219 (2011).
89. White DM, Pellett S, Jensen MA, Tepp WH, Johnson EA, Arnason BG. Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells. Infect. Immun. 79(8), 3388-3396 (2011).
90. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin. Infect. Dis. 53(3), 296-302 (2011).
91. van Ginkel FW, Jackson RJ, Yuki Y, McGhee Jr. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165(9), 4778-4782 (2000).
92. ClinicalTrials.gov. Double blind, safety and immunogenicity study of recombinant botulinum vaccine A/B. http://clinicaltrials.gov/ct2/show/NCT007 64634?term=botulism&rank=8 (Accessed 12 January 2012)
93. The National Select Agent Registry. www.selectagents.gov (Accessed 12 June 2012)